Abstract:Background: Radiologically Isolated Syndrome (RIS) likely represents the earliest detectable form of multiple sclerosis (MS). There are recognized risk factors for conversion of RIS to clinically definite central nervous system (CNS) demyelinating disease. We aim to characterize a new clinical cohort with RIS and to analyze previously established risk factors for conversion to clinically definite disease. Methods: A medical records search was performed for patients who were diagnosed with RIS by their treating neurologist at our institution in Boston, USA, from January 2005 to April 2020. Demographic data, clinical outcomes, and treatment courses were analyzed. The time to first clinical event representing a demyelinating disease attack or last follow up without clinically definite disease was calculated for each person. Hazard ratios (HRs) for known risk factors for the conversion of RIS to clinically definite disease were calculated using Cox proportional hazards models. Results: Of 89 patients, the median age at RIS diagnosis was 41.0 years (76% female, 8% with a family history of MS and 16% of any autoimmune disorder, 66% never smokers, 40% BMI >30 kg/m2, 45% with spinal cord MRI lesions). Clinically definite disease was observed in 16 patients (18%) during follow-up (median time to first event 3.4 years; median follow-up duration of full cohort 3.8 years). Median EDSS for those who developed clinically definite disease was 1.25 (range: 0-4) at most recent follow up. Of 84 patients with longitudinal brain imaging, 42 (50%) had new demyelinating lesions. Gadolinium-enhancing lesions were seen in 36 patients (43%) at either baseline (n=24) or follow-up (n=12). Most patients had at least one T1-hypointense lesion (n=70, 83%). Five patients underwent ultra-high field MRI (7 Tesla); all were positive for central vein sign, two demonstrated leptomeningeal enhancement, and one was found to have cortical lesions. Out of 30 patients with susceptibility-weighted imaging acquired during routine clinical care, 8 had at least one paramagnetic rim positive lesion. Previously reported risk factors for conversion to MS were not significant: age ≤37 years HR 1.3 (95% confidence interval (CI), 0.47-3.5), male sex 1.5 (95% CI, 0.41-5.2), and spinal cord lesions 1.3 (0.47-3.4). Nearly one-third of RIS patients (n=26) took a disease modifying therapy (DMT) for MS (median total treatment duration on any DMT=2.7 years). The sub-cohort treated with a DMT had a statistically significantly greater number of recognized risk factors for conversion to clinically definite disease compared with the untreated group (p=0.028). Most patients took a DMT for MRI changes demonstrating new demyelinating disease activity (n=16). Dimethyl fumarate (n=9) and glatiramer acetate (n=7) were the most frequently prescribed DMTs. A second-line DMT was started in 10 patients. Conclusion: We characterize a new cohort of RIS patients, demonstrating time to clinically evident demyelinating disease from RIS diagnosis of approximately 3.4 years. Our data suggest that early use of a DMT in RIS may mitigate the impact of recognized risk factors on the occurrence of clinically evident disease and reduce the likelihood of conversion to clinically definite CNS demyelinating disease in high-risk individuals.

Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis

IgG Index for Multiple Sclerosis Diagnosis: Old Test Do the Trick (2064)

Analysis of Factors Correlated with Spinal Clinically Isolated Syndrome Conversion to Multiple Sclerosis.

IgG Index Revisited: Diagnostic Utility and Prognostic Value in Multiple Sclerosis

Intrathecal immunoreactivity in people with or without previous infectious mononucleosis

Complement Activation Is Associated With Disease Severity in Multiple Sclerosis

The presence of oligoclonal bands predicts conversion to multiple sclerosis in isolated myelitis

Intrathecal IgG and IgM synthesis correlates with neurodegeneration markers and corresponds to meningeal B cell presence in MS

Progression predictors of clinically isolated syndrome to multiple sclerosis: A prospective study in China

Lymphocyte profiles after a first demyelinating event suggestive of multiple sclerosis reveal early monocyte and B cell alterations

Radiologically isolated syndrome: A single-center, retrospective cohort study

Intrathecal kappa free light chains as markers for multiple sclerosis

Intrathecal immune reactivity against Measles-, Rubella-, and Varicella Zoster viruses is associated with cerebrospinal fluid inflammation in multiple sclerosis

Intrathecal B cell activation and memory impairment in multiple sclerosis

Intrathecal IgM synthesis as a diagnostic marker in patients with suspected CNS lymphoma

Long-term clinical, imaging and cognitive outcomes association with MS immunopathology

Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis

Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury

Prognostic relevance of the C‐X‐C motif chemokine ligand 13 and interleukin‐8 in predicting the transition from clinically isolated syndrome to multiple sclerosis

Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5

HLA Associations of Intrathecal IgG Production against Specific Viruses in Multiple Sclerosis